We rank companies based on fund manager, research analyst and news sentiment
ABVC stock icon

ABVC BioPharma, Inc. Common Stock


About: ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.

Employees: 19

Funds holding %
of 6,474 funds
Analysts bullish %
News positive %
of 3 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

61% more capital invested

Capital invested by funds: $79.8K [Q3] → $129K (+$48.7K) [Q4]

0.51% less ownership

Funds ownership: 1.94% [Q3] → 1.43% (-0.51%) [Q4]

11% less funds holding

Funds holding: 9 [Q3] → 8 (-1) [Q4]

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Research analyst outlook

We haven’t received any recent analyst ratings for ABVC.

Financial journalist opinion

Based on 3 articles about ABVC published over the past 30 days